Feng Xun Life Sciences completed nearly 60 million yuan in seed and angel funding.

On November 10th, Nantong Fengxun Biotechnology Co., Ltd. announced the completion of seed and angel round financing, with investors including Han Yuan Asset Management, Junlian Capital, Zhongke Chuxing, Shengjing Investment, Hongfeng Investment, etc. The funding will be used to accelerate the evolution of the core technology platform, team building, and the clinical transformation and development of the first candidate product in the fields of hematologic malignancies, autoimmune diseases, etc.